�
25~40%
� � � � � NSCLC � � � � � � � �
1,2
1. Owen S, SouhamiL. Front Oncol2014;4:248 2. Economopoulou P, et al. Trans Lung Cancer Res 2016;5:588–98 3. IuchiT, et al. Int J Clin Oncol2015;20:674–9 4. Schuler M, et al. J
ThoracOncol2016;11:380–90. 5. .J Thorac Oncol. 2014 ; 9(2):195-9. 6. J Thorac Oncol. 2016 Jul 22. pii: S1556-0864(16)30626-8. 7. Li YS, Jiang BY, Wu YL. J Thorac Oncol. 2016
Nov;11(11):1962-1969. 8. Mack F, et al. Cancer Treat Rev. 2016;43:83-91. 9. Leal T, et al. Curr Cancer Ther Rev. 2011;7(4):319-327. 10. � � � � � � � � � � � � � � � � � � � � � � � ——2018 � 01 � � � .
3%-5%
� � � �
1
EGFR � � � � � � � � �
� � � � 40~60%
3 � 4
2
EGFR � � � � � � � � � � � � � � � � � � � � �
(9.4% vs 1.7% � P<0.001)
6
� � � � � � �
�
� � � �
� � �
� �
� � � � � � � � � �
� � � � �
� � � �
� � �
�
�
�
�
� � �
� � � � �
�
�
�
�
�
�
�
�